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Abstract Deleterious germ-line variants involving the
DNA mismatch repair (MMR) genes have been identified
as the cause of the hereditary nonpolyposis colorectal
cancer syndrome known as the Lynch syndrome, but in
numerous familial clusters of colon cancer, the cause
remains obscure. We analyzed data for 235 German-
speaking Swiss families with nonpolyposis forms of colo-
rectal cancer (one of the largest and most ethnically
homogeneous cohorts of its kind) to identify the pheno-
typic features of forms that cannot be explained by MMR
deficiency. Based on the results of microsatellite instability
analysis and immunostaining of proband tumor samples,
the kindreds were classified as MMR-proficient (n = 134,
57%) or MMR-deficient (n = 101, 43%). In 81 of the latter
kindreds, deleterious germ-line MMR-gene variants have
already been found (62 different variants, including 13
that have not been previously reported), confirming the
diagnosis of Lynch syndrome. Compared with MMR-
deficient kindreds, the 134 who were MMR proficient were
less likely to meet the Amsterdam Criteria II regarding
autosomal dominant transmission. They also had primary
cancers with later onset and colon-segment distribution
patterns resembling those of sporadic colorectal cancers,
and they had lower frequencies of metachronous colorectal
cancers and extracolonic cancers in general. Although the
predisposition to colorectal cancer in these kindreds is
probably etiologically heterogeneous, we were unable to
identify distinct phenotypic subgroups solely on the basis
of the clinical data collected in this study. Further insight,
however, is expected to emerge from the molecular char-
acterization of their tumors.
Keywords Colorectum  Familial cancer  Lynch
syndrome  Mismatch repair  Switzerland
Abbreviations
MSI Microsatellite instability
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AC II Amsterdam criteria II
rBG Revised Bethesda
guidelines
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MLPA Multiplex-ligation dependent-
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FCC-X Familial colorectal cancer
type-X
HNPCC Hereditary nonpolyposis
colon cancer
FAP Familial adenomatous polyposis
MMR-deficient
or-proficient FCC
Mismatch repair deficient or
proficient, familial colorectal cancer
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Introduction
Colorectal cancer is one of the most frequent cancers in
humans, and its incidence is highest in the so-called
developed countries. Given its high prevalence, it is not
surprising that the disease sometimes strikes more than one
member of a single family. Aggregations of cancer within
kindreds are usually referred to as familial, which does not
necessarily mean the disease is genetically inherited. Few
familial clusters of colorectal cancer are believed to be
associated with a single genetic alteration: in most cases,
the cancer predisposition probably stems from some com-
bination of genetic and/or epigenetic, environmental, and/
or behavioral factors (in particular, physical activity and
diet). The variable contributions of these factors might
result in diverse types of cancer, each with relatively dis-
tinct clinical and molecular characteristics.
Colorectal cancer syndromes with predominantly
genetic causes have been thoroughly described in many
countries. Several of the syndromes associated with the
extensive formation of colorectal polyps have been traced
to alterations in specific genes (e.g., familial adenomatous
polyposis, which is caused mainly by deleterious germ-line
alterations in the APC gene), but these forms are relatively
rare. In most hereditary colon cancer syndromes, the
number of adenomatous polyps is by no means exceptional,
which makes it less likely that the syndrome will be
identified on the basis of clinical findings alone.
Thus far, only one of these syndromes has been linked to
specific genetic alterations: the Lynch syndrome. In this
case, the increased risk of cancer (which involves not only
the colon but also the endometrium and other organs) stems
from germ-line defects involving one of four genes
involved in DNA mismatch repair (MMR) (reviewed in
[1, 2]). Mismatch repair deficiency can be diagnosed with
assays of tumor DNA for microsatellite instability (MSI)
and immunostaining of tumor sections for the major MMR
proteins. When defects are found, germ-line DNA can then
be analyzed to find the deleterious variant causing the
disease. Once this variant has been pinpointed, carriers
within an affected kindred can be identified and measures
taken to prevent them from developing colon cancer.
Unfortunately, in most families with familial colon
cancer (FCC) syndromes, this work-up reveals no MMR
deficiency, and the basis of their predisposition to colo-
rectal cancer thus remains unknown. In the present study,
we prospectively analyzed a large number of Swiss kin-
dreds with FCC. Our aim was to identify the phenotypic
features of MMR-proficient, non-polyposis, colon cancer
syndromes (a subset that probably includes several etio-
logically distinct forms of disease) and to see how they
differ from those of similar syndromes linked to MMR
deficiency.
Patients and methods
The study was approved by the Cantonal Ethics Committee
of Basel, Switzerland (No. 258/05), and each subject
investigated provided written informed consent to genetic
testing, collection and analysis of data, and publication of
the findings. Unless, otherwise specified, all commercial
products mentioned below were used in accordance with
manufacturers’ instructions.
Kindreds
From 1997 to 2008, we enrolled a total of 509 unrelated
kindreds with FCC, all living in the German-speaking
cantons of Switzerland (total resident population: *5 mil-
lion). The probands were referred to our staff by private and
hospital-based practitioners for various reasons. One of the
most common was that the colorectal cancer was associated
with multiple colorectal polyps (10 or more) because the
Research Group in Human Genetics of the University of
Basel (MK and KH) is also a referral center for patients with
gastrointestinal polyposis. As a result, an unrepresentatively
large proportion of the enrolled kindreds were ultimately
found to have polyposis-related cancer syndromes.
The present analysis was restricted to the 235 kindreds
who did not fall into this category and whose probands
found to have nonpolyposis forms of FCC (Fig. 1). At the
time of referral, all 235 probands had family histories
satisfying at least one of the following criteria: (1) diag-
nosis at any age of colorectal, gastric, duodenal, small
intestinal, endometrial, or ovarian cancer (the cancers most
frequently associated with the Lynch and polyposis syn-
dromes) in the proband and in at least one of his/her first-
degree relatives; or (2) diagnosis of one or more of the
cancers listed above in the proband only, but at an age of
50 years or younger.
Medical information for these families has been pro-
vided by probands and/or family members themselves or
by the latters’ physicians. Whenever possible, we also
reviewed the actual medical charts, pathology reports, and
death certificates. Detailed pedigrees (minimum: 2 gener-
ations) have been created with Cyrillic v2.1.3 software
(Cherwell Scientific Publishing, Oxford, UK), and each has
been carefully analyzed to determine whether it fulfilled
the Amsterdam criteria II (AC II) and/or the revised
Bethesda Guidelines (rBG) [1].
Protocol for diagnosing Lynch syndrome
DNA extraction from peripheral blood and tumor tissue
Germ-line DNA was isolated from the peripheral blood of
the probands with the salting-out procedure described by
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Miller et al. [3]. Tumor DNA was extracted from formalin-
fixed, paraffin-embedded tissues with the Ambion Recov-
erAllTM tissue kit (Applied Biosystems, Foster City, CA,
USA). Hematoxylin and eosin-stained sections of the tissue
block were examined to locate a representative portion of
the tumor with an average epithelial content of[70%, and
this portion was dissected for DNA extraction.
Analysis of microsatellite instability
and immunohistochemistry
In accordance with National Cancer Institute recommen-
dations [4], we analyzed tumor DNA for microsatellite
instability (MSI) at 5 loci (BAT25, BAT26, D5S346,
D17S250, and D2S123) using a capillary sequencing pro-
tocol that has been previously described [5]. Only those
tumor phenotypes classified as MSI-high (instability at 2 or
more of the 5 [40–100%] loci) were considered indicative
of MMR deficiency. For the purposes of the present anal-
ysis, findings were classified as negative when they
revealed instability at only 1 [20%] of the 5 loci (MSI-low
phenotype) or absence of instability at all 5 loci (micro-
satellite-stable [MSS] phenotype).
MMR protein expression was assessed in tumor sections
with standard immunohistochemical (IHC) techniques, as
described elsewhere [6], and antibodies against each of the
4 major MMR proteins (MSH2, MSH6, MLH1, and PMS2)
[7].
On the basis of MSI and IHC findings, probands were
classified as having MMR-deficient tumors (MSI-high and/
or loss of expression of one or more of the 4 MMR pro-
teins) or MMR-proficient tumors (all others).
Analysis of MMR genes for deleterious variants
In patients with MMR-deficient tumors, MMR genes were
analyzed in germ-line (leukocyte-derived) DNA. When
possible, this analysis was restricted to the gene identified
in IHC as the one most likely to harbor the primary alter-
ation responsible for the disease (see ‘‘Results’’ for details).
Otherwise, we analyzed all 4 MMR genes.
First, we sequenced the MMR gene(s) using BigDye
Terminator chemistry (version 1.1, Applied Biosystems,
Foster City, CA, USA). (Primer sequences and PCR con-
ditions are available on request.) Results indicative of a
deleterious variant were confirmed in a second, indepen-
dently drawn blood sample. The probability that missense
variants exerted damaging effects on the function of their
protein products was estimated with the PolyPhen-2 scor-
ing system, as described by Adzhubei et al. [8].
When sequencing findings were negative, the DNA
sample was screened for copy number aberrancy with
multiplex-ligation dependent-probe amplification (MLPA)
kits P003 (for MLH1, MSH2, and EPCAM); P008 (MSH6
and PMS2); and P072 (for MSH6 only) (MRC Holland,
Amsterdam, The Netherlands). GeneMarker software (Soft-
Genetics, State College, PA, USA) was used for identifi-
cation and dosage quotient analysis of each specific
amplicon. (Dosage quotients of*1 indicate the presence of
2 copies of a given gene; quotients of *0.5 indicate loss of
1 copy.) MLPA results indicative of a germ-line deletion
were confirmed in a second, independently drawn blood
sample. All apparently single-exon deletions were directly
sequenced to identify possible sequence variations within
the ligation-probe binding site, which can mimic single-
exon deletions.
When positive findings emerged from either of the
above studies, the kindred was definitively classified as
having Lynch syndrome. If no deleterious variants were
identified in the germ-line with these methods, kindreds
whose tumors were MMR-deficient were classified as
having probable Lynch syndrome and genetic testing
continued to identify the causative alteration.
235 probands 
83 AC II (+) 152 AC II (-)  
and rBG (+) 
AC II and rBG 
application 
MSI analysis 
26 MSS  /  57 MSI-H 109 MSS  /  43 MSI-H 
Immunohisto- 
chemistry (IHC) 
MSH6(-): 1 
All 4 MMR 
proteins + : 25 
MSH2(-): 22 
MSH6(-): 1 
MLH1(-): 32 
PMS2(-): 1 
All 4 MMR 
proteins + : 1 
MSH2(-): 18 
MSH6(-): 3 
MLH1(-): 17 
PMS2(-): 5 
Sanger sequencing 
 and MLPA 
All 4 MMR 
proteins + : 
109 
MSH2: 19/22 
MSH6: 1/1 
MLH1: 32/32 
PMS2: 0/1 
All 4 MMR 
proteins + : 1/1 (MLH1) 
MSH2: 14/18 
MSH6: 3/3 
MLH1: 9/17 
PMS2: 1/5 
MSH6: 1/1 
 101 MSI-H and/or IHC(-):  MMR-deficient familial colorectal cancer 
 134 MSS & IHC(+):  MMR-proficient familial colorectal cancer 
Fig. 1 The diagnostic flow chart used to classify the 235 probands’
families having MMR-deficient or MMR-proficient familial colorec-
tal cancer. See ‘‘Results’’ for details
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Statistical analysis
We compared the groups with MMR-deficient and MMR-
proficient FCC to identify differences regarding sex, age at
first cancer diagnosis, mutational status, etc. (variables
shown in all tables). Differences were analyzed with the
Fisher exact test (for categorical variables) or the Student
t test (for continuous variables). All probabilities are
reported as two-tailed P values, considering P \ 0.05 to be
statistically significant.
We then used multivariate analysis to identify clusters of
patients within the two main groups (MMR-proficient and
MMR-deficient FCCs) with similar clinical and molecular
profiles. Thirteen clinical variables (sex; age at first cancer
diagnosis; type of first cancer; type of second cancer; spe-
cific site of the first cancer; and occurrences of colorectal,
small bowel, stomach, endometrial, ovarian, brain, urothe-
lial cancer, and colorectal adenomatous polyps) and 2
molecular features of tumors (MSI and expression of MMR
proteins) were considered in this analysis. Several multi-
variate data analysis algorithms (symmetric and nonsym-
metric correspondence, redundancy analyses) [9–11] were
used to detect patient subgroups within the two main groups
and to predict membership of patients in a given molecular
cluster based on their clinical profiles, or vice versa.
Results
From 1997 to the end of 2008, we enrolled 509 unrelated
Swiss kindreds that met the minimal inclusion criteria
described above. As noted in ‘‘Patients and methods’’, 274
were found to have hereditary polyposis syndromes or
multiple colorectal adenomas (C10 adenomatous polyps)
and were excluded from the present analysis.
Figure 1 summarizes the results of our analysis of the
235 kindreds (703 affected individuals) with nonpolyposis
forms of FCC. Pedigree data for 3 or more generations
were available for 70% of these kindreds and for 2 gen-
erations in the remaining 30%. Eighty-three (35%) families
fulfilled the AC II; the remaining 152 (65%) satisfied one
or more of the inclusion criteria of the rBG.
On the basis of the results of MSI analysis and IHC of
tumor samples from the probands, the FCC in 101 (43%) of
these 235 kindreds was classified as MMR-deficient
(n = 101, 43%). The other 134 (57%) were MMR-profi-
cient [12, 13]. As shown in Fig. 1, MSI and IHC findings
were concordant in 99 of the 101 MMR-deficient probands
(i.e., MSI-H plus loss of expression of at least 1 MMR
protein). In 79 of these cases, mutation screening of germ-
line DNA revealed a deleterious variation in the unex-
pressed MMR gene (Supplementary Table 1), thereby
confirming the diagnosis of Lynch syndrome. In two other
cases, the classification of MMR deficiency was supported
by only one of the two methods (MSI or IHC). In both
cases, however, mutation screening confirmed the diagno-
sis of Lynch syndrome. One of these (case no. 2047/01)
involved an MSI-H tumor in which all 4 MMR proteins
were normally expressed. Screening of all 4 MMR genes
revealed a missense variant at the MLH1 locus [c.292G [
C(p.Gly98Arg)], which was classified as ‘‘damaging’’ on
the basis of the PolyPhen-2 score [8]. The second dis-
crepancy involved case no. 2467/01. This individual had an
MSS tumor that did not express MSH6, and a nonsense
variant was indeed found in the gene that encodes this
MMR protein (Supplementary Table 1).
On the whole, 81 (80%) of the 101 MMR-deficient pro-
bands were confirmed as having the Lynch syndrome by
sequencing and/or MLPA-based documentation of a dele-
terious variants at one of the major MMR loci. A total of 62
different variants were found, including 8 carried by two or
more probands. Thirteen of the mutations appeared to be
novel in that they were not listed in the Memorial University
of Newfoundland MMR-Gene Variant Database [14] or in
the Leiden Open Variation Database [15]. As shown
in Supplementary Figure 1, the 33 variants detected in
MSH2 included 9 nonsense alterations, 1 missense variant, 9
in-frame deletions, and 14 small insertions, deletions, or
splice site variants that caused reading-frame shifts resulting
in premature termination of translation. All 5 of the MSH6
alterations were nonsense variants. The 42 variants
detected in MLH1 included nonsense (n = 6) and missense
(n = 5) variations, in-frame deletions (p.Lys616del
[n = 5], p.Glu578_Glu633del [n = 2], p.Val664_Gln701-
del [n = 7]), and 17 small insertions, deletions, or splice site
variants that shifted the translation frame. As for PMS2, only
1 nonsense variant has been identified thus far. The family is
1 of the 6 with PMS2-deficient tumors. All 6 of the missense
variants we have found (5 involving MLH1 and 1 MSH2)
were considered to be deleterious on the basis of their
PolyPhen-2 scores (Supplementary Table 1).
In the remaining 20 probands with MMR-deficient
tumors (7 with loss of MSH2, 8 with loss of MLH1, and 5
with loss of PMS2), no pathogenic germ-line variants in
MMR genes could be identified by Sanger sequencing or
gene copy number analysis by MLPA. Technically speaking
then, the presence of Lynch syndrome in these kindreds
cannot be confirmed at this time. Further testing, however,
might well reveal germ-line alterations of a genetic nature in
regions of the MMR genes not covered by our analyses (e.g.,
intronic changes or those involving the 50 or 30 UTR) and/or
epigenetic changes (e.g., promoter hypermethylation).
The next step was to identify phenotypic differences
between the MMR-deficient and MMR-proficient FCC
subsets. Table 1 shows the clinical characteristics of the
probands in these two groups. The MMR-deficient group
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exhibited: (1) a higher probability of fulfilling the AC II
(57.4% [58/101] versus 18.6% [25/134] of the MMR-pro-
ficient FCC group; Fischer’s exact P value \ 0.001); (2)
earlier onset of the primary cancer (by *4 years compared
with MMR-proficient FCC probands; P = 0.013); (3) a
higher proportion of primary colon cancers that were
located in the proximal colon (52.5% [53/101] versus
18.6% [25/134] of the probands with MMR-proficient
FCC; P \ 0.001); (4) a higher frequency of metachronous
cancers of the colorectum (P = 0.036); and (5) a higher
frequency of cancers in extracolonic organs specified in the
rBG (P \ 0.001), particularly the endometrium. MMR-
deficient probands also exhibited a trend toward better
survival at 5 years. (Only 5 of the 27 probands who died
within 5 years of diagnosis were members of this group.)
The two groups of probands were similar in other respects,
including sex ratios and the presence of synchronous
colorectal cancers or synchronous and metachronous
colorectal adenomas.
Next, we analyzed the clinical features reported in
Table 1 in the total population investigated in this study
(i.e., all 703 affected individuals, including the 235 pro-
bands in Table 1 and their 468 relatives) (Table 2). For the
purpose of this analysis, tumors that could not be analyzed
for MMR-deficiency (specimens unavailable) were pre-
sumptively classified as having the same MMR status as
the corresponding proband’s tumors. The accuracy of this
classification is obviously less than 100%, but its general
reliability is supported by two findings. First, all of the non-
proband tumors that were available for MSI analysis and
IHC (approximately 15% of all those reported) had MMR
statuses identical to those of the corresponding proband’s
tumors. Second, the affected family members were almost
all first- (n = 239; 51.1%) or second-degree (n = 143;
30.5%) relatives of their respective probands; only 86
(18.4%) were third-degree relatives.
Using this approach, we estimated that 395 (56.2%) of
the 703 individuals considered (101 probands and 294 of
their relatives) had MMR-deficient tumors, and 308 (134
probands, 174 of their relatives) had MMR-proficient FCC.
As shown in Table 2, the clinical features that distin-
guished MMR-deficient and MMR-proficient groups in the
extended population were the same ones that differentiated
these 2 groups in the proband population. In this case,
however, the MMR-deficient group was also characterized
by a significantly lower age at the diagnosis of colorectal
adenomas [P = 0.025 versus the MMR-proficient FCC
subgroup]. This difference had not been statistically sig-
nificant when the probands were compared (probably
owing to the smaller size of these groups), but it came as no
surprise because both the proband and extended MMR-
deficient FCC populations exhibited significantly earlier
onset of primary colorectal cancers than their counterparts
with MMR-proficient FCC. Comparison of Tables 1 and 2
shows that the ages at diagnosis of primary cancers in both
extended populations were *5 years higher than those
observed among the respective proband populations. This
difference reflects a selection bias related to the docu-
mented tendency to enroll younger individuals in cancer
screening programs, and it is consistent with previous
reports [16]. More details on the clinical features of the 235
probands and the extended population of affected individ-
uals are reported in Supplementary Tables 2 and 3,
respectively, where AC II(?) and AC II(-) subgroups are
compared.
The multivariate analysis described in ‘‘Patients and
methods’’ was performed in the proband and extended
populations. In both cases, it readily discerned the MMR-
deficient FCC and MMR-proficient FCC clusters, as well
as those defined by sex (because of the high incidence of
endometrial cancer associated with colorectal cancer), but
no evident sub-clusters could be identified within either
these two obvious groups (data not shown).
Discussion
Apart from the rare inherited colorectal polyposis syn-
dromes, the only hereditary colorectal cancer syndrome
that has been linked to a specific genetic alteration is the
Lynch syndrome, which stems from germ-line defects in
the DNA MMR genes. Using a combination of MSI anal-
ysis of tumor DNA and IHC assessment of MMR protein
expression in tumor sections, we found that 101 of the 235
probands we studied had MMR-deficient tumors, and the
presence of Lynch syndrome was confirmed in 81 of the
cases by the demonstration of deleterious variants at a
major MMR locus in the germ-line DNA.
The two-pronged approach we used revealed 2 cases of
MMR-deficiency (both of which were later confirmed as
Lynch syndrome) that would have been missed if MSI
analysis or MMR IHC had been used alone. In general,
however, the two methods yielded concordant results. This
is largely due to the fact that we perform immunostaining
for all 4 MMR proteins, a practice dictated by the relative
stability of the MMR proteins within the heterodimers they
form (MSH2/MSH6 and MLH1/PMS2) [6, 7]. It also
reflects the quality of tumor-block fixation and paraffin
embedding procedures in most of Switzerland’s pathology
laboratories, an absolute prerequisite for reliable IHC
assessment.
IHC was also highly sensitive in detecting tumors har-
boring damaging missense variants at MMR loci. A single
amino-acid substitution does not always produce protein
destabilization that is detectable with this approach (as we
saw in the patient with the missense variant in MLH1
Familial colorectal cancer in Switzerland 609
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described above). However, the other 5 germ-line missense
variants found in our MMR-deficient probands thus far
(4 involving MLH1, 1 in MSH2) were all associated with
negative staining for the protein encoded by the affected
gene (MLH1 or MSH2) and for the affected protein’s
heterodimeric partner (PMS2 or MSH6, respectively).
Using antibodies against all 4 MMR proteins provides
intrinsic controls that allowed us to restrict our initial
mutational analysis to a single MMR gene. In 80% of the
cases tested thus far, this approach has successfully dis-
closed pathogenic germ-line variants, including 13 that
have not been previously reported. A positive ‘‘side effect’’
of our study is that most pathology laboratories in Swit-
zerland are now using MMR protein IHC to investigate
tumors when FCC is suspected.
Despite its relatively high prevalence, Lynch syndrome
accounted for only *35% of the nonpolyposis forms of
FCC in our registry (81 MMR-deficient probands in whom
a deleterious MMR gene variants has been detected so far).
Deleterious variants might also conceivably be discovered
in some or all of the 20 MMR-deficient probands with
probable Lynch syndrome, who are undergoing additional
tests for the detection of genetic and epigenetic variations
(see ‘‘Results’’). In the other kindreds (*60% of those
studied), the inherited (genetic, epigenetic) and noninher-
ited causes of the predisposition to colorectal cancer are
currently unknown. This type of disease is often referred to
as familial colorectal cancer type-X (FCC-X) when the
inheritance pattern is Mendelian or common familial risk
colorectal cancer when it appears to be associated with
intermediate-penetrance alleles [12, 13, 17]. For the sake of
simplicity, we will refer to both forms hereafter as MMR-
proficient FCC.
The clinical phenotypes of MMR-deficient and MMR-
proficient FCC have been compared in various parts of the
world, including Europe [12, 18–25], North America [12,
26], and Australasia [12, 27, 28]. Lindor et al. reported
another large, well-characterized series of FCC kindreds
from different countries (all fulfilling the original AC, also
called AC I [29]) [12]. The phenotypic differences they
observed between Lynch syndrome families (n = 90) and
those with FCC-X (n = 71) were clearly present in the 235
Swiss kindreds we examined. In our series, individuals with
inherited defects involving DNA MMR presented with
colorectal cancer earlier in life (*5 years) than those
whose MMR system was intact, and their cancers were
much more likely to be located in the proximal colon. Their
phenotype was also patently syndromic with an increased
tendency to develop second primary tumors in the large
intestine and extracolonic cancers (mainly endometrial) as
well. These differences were still evident when we extended
our analysis to the probands’ affected relatives (Table 2).
The overall incidence of cancer (colorectal and other
types) was also higher in the MMR-deficient kindred
subset, which comprised 294 affected blood relatives in
addition to the 101 probands. (By comparison, the MMR-
proficient FCC group included 134 probands but only 174
affected relatives.) This substantially higher penetrance for
colorectal and extracolonic cancers explains why MMR-
deficient families were more likely to meet the AC II
(57.4% versus 18.6% of those with MMR-proficient FCC).
Optimal clinical management strategies for these two
subsets of familial colorectal cancer will naturally differ in
several respects, including the starting age and frequency
of surveillance colonoscopy in family members and the
extension of preventive diagnostics to organs other than the
colon. Last but by no means least, members of Lynch
syndrome families who do not harbor the deleterious MMR
gene variant can be spared the ordeal of the high-frequency
surveillance recommended for the carriers (although they
should still follow population screening guidelines). This is
not possible in MMR-proficient FCC families. Until the
inherited genetic alteration(s) responsible for these cancers
are identified, all members of these families need to
undergo frequent check-ups.
Stringent clinical criteria like the AC are the starting
point in the search for genetic loci that might be respon-
sible for cancer predisposition. This approach has led to the
identification of numerous Mendelian disorders, but the
discovery of the cause of the Lynch syndrome was much
more fortuitous. It stemmed from the observation of MSI in
the tumors associated with this syndrome, a phenomenon
that had already been linked to DNA MMR in lower
organisms (reviewed in [30]). The germ-line variants in the
MUTYH gene that cause colorectal polyposis were also
identified thanks to clues gleaned through the molecular
characterization of somatic alterations in tumors (reviewed
in [31]).
What can these experiences teach us regarding the
search for the cause(s) of MMR-proficient FCC? For one
thing, if the genetic approach is to be used, it is essential to
remember that MMR-proficient FCC is not a single entity.
It almost certainly encompasses several different condi-
tions, some of which are classic Mendelian disorders while
others are more complex, multifactorial diseases with
variable genetic, epigenetic, behavioral, and environmental
components. As shown in Fig. 1, 25 of our kindreds had
tumors that were microsatellite-stable and appeared to
express all four of the major MMR proteins. And yet their
pedigrees satisfied the AC II. It is in this group of families
that the possibility of a predominantly genetic etiology
should be explored using Mendelian genetics, even though
efforts along these lines conducted thus far have not (to our
knowledge) been successful.
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In other MMR-proficient FCC kindreds, multiple factors
presumably contribute to the onset of colorectal cancer.
Ferreting these out will undoubtedly prove to be a much
more complicated task. The tools of quantitative genetics
are better suited to this purpose since they also take into
consideration behavioral and environmental contributions,
which are thought to be highly important in the inheritance
of such cancers. Multivariate analysis based on the clinical
variables documented by our team failed to identify dif-
ferent subgroups among our MMR-proficient FCC kin-
dreds. This suggests that greater effort should go into the
clinical characterization of probands and their families
during recruitment for such studies.
The search for etiologic factors in MMR-proficient FCC
could also be jump-started by a more complete biological
characterization of the tumors themselves. The molecular
phenotype(s) of these cancers (like those associated with
the Lynch syndrome and colorectal polyposis) hold
important clues that could point the search in the right
direction. A high-throughput, –omics-based analysis of
these phenotypes might provide productive hints on their
etiology. A systems biology approach that analyzes data on
the MMR-proficient FCC tumors’ (epi)genome, transcrip-
tome, proteome, and metabolome could allow us to make
an informed guess as to their cause(s), which could then be
experimentally tested. The value of this approach has been
confirmed by previous experience with the MMR-deficient
colorectal cancers, where a striking phenotype was
accompanied by peculiar genomic [32] and transcriptomic
patterns [33].
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